

C-fiber-Selective Peripheral Nerve Blockade

Suzuko Suzuki^{1,*}, Peter Gerner², Anna C Colvin³ and Alexander M. Binshtok⁴

¹Department of Anesthesiology and Perioperative Medicine, Pain Research Center, Brigham and Women's Hospital, MRB-611 75 Francis Street, Boston, MA 02115; ²Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; ³Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women's Hospital and Harvard, Medical School, Boston, MA; ⁴Department of Anesthesia, and Critical Care, Massachusetts General Hospital and Harvard, Medical School, Charlestown, MA

Abstract: Despite the clinical demand, current uses of local anesthetics do not allow selective blockade of nociceptive fibers. Regional anesthesia produces an analgesic effect accompanied with undesired side effects due to block of motor, non-nociceptive sensory and autonomic fibers. These side effects limit the clinical use of local anesthetics and affect the recovery and rehabilitation period after surgical procedures. Therefore one main goal of research in the field of regional anesthesia is selectively targeting nociceptive fibers. Recent studies describing the role of nociceptive specific sodium channels in generation and propagation of nociceptive signals make these channels ideal targets for pain selective blockade. In addition, novel methods of targeted delivery of charged local anesthetics selectively into nociceptors provide another potentially successful approach for c-fiber specific nerve block. This review summarizes currently on-going studies on several promising targets and methods to achieve pain selective anesthesia.

INTRODUCTION

Local anesthetics (LAs) are frequently used in clinical practice when anesthesia of limited body area is desired. LAs block voltage-gated sodium channels, thereby preventing generation of action potentials and their propagation along the nerve [1]. However, LAs block sodium channels not only in sensory fibers but also in motor and sympathetic fibers. To date, no agent or method translatable into current clinical practice has been shown to elicit usable pain-selective nerve blocks. In general, clinicians agree that there is a slight but detectable difference among local anesthetics in motor vs. sensory blockade; e.g., bupivacaine in general has somewhat more sensory/nociceptive block than motor block, while etidocaine confers more motor than sensory block. The following pages review treatments that are far more selective or exclusively pain-fiber selective than currently used clinical and experimental local anesthetics. Nociceptive-selective nerve block has been attempted with concentrations of LAs that are high enough for only certain nerve fibers (smaller-diameter, thinly myelinated A-delta or unmyelinated C-fibers), but not for others (larger-diameter, myelinated nerves such as A-beta). Nevertheless, studies have demonstrated that nerve block does not always follow this size principle, and motor fibers are blocked before nociceptive fibers [2]. Therefore, complete pain relief is generally accomplished only with simultaneous low-threshold sensory sympathetic and motor blockade, leading to numerous adverse effects. Improving the sensory-selectivity of LAs will clearly extend their clinical utility. (Of note, especially in the clinical

anesthesia literature, the terms “sensory-selective” and “differential block” are commonly used and are roughly interchangeable with “pain-selective” and “nociceptor-selective.”) We review novel methods to achieve nociceptor-selective peripheral nerve blockade.

Considering the properties of pain-specific peripheral nerve fibers is fundamental in exploring differential nerve blockade. Noxious stimuli are received and interpreted by selective-type peripheral sensory neurons, i.e. nociceptors. Nociceptors are unique among other peripheral neurons for their expression of high-threshold transducer receptors that transform noxious chemical, thermal, and/or mechanical stimuli into electrical signals [3]. Those receptors include channels from the transient receptor potential family; TRPV1, V2, M8, A1, and the purinoreceptor P2X [4-6]. TRPV1, V2, and M8 are involved in perception of heat [4, 5, 7, 8], and A1 is involved in sensing various chemical irritants [9]. Purinoreceptor P2X is activated by the presence of ATP [10]. The activation of these receptors results in ion influx and depolarization of the membrane of the nerve terminal [11]. If the depolarization is strong enough to activate sodium channels, it will result in action potentials that propagate along A delta and C fibers. These nociceptors express a unique repertoire of sodium channels including both TTX-sensitive and -resistant subtypes. A-delta fibers are associated with transmission of superficial, sharp pain. The C fibers are associated with transmission of dull, throbbing pain [12]. It is now agreed that within the peripheral nervous system C-fibers express TRPV1 and Na_v1.7 almost exclusively [13-17]. Therefore this review focuses mainly on TRPV1 and Na_v1.7.

TRPV1 CHANNELS

The vanilloid receptor subtype 1 (VR1) (TRPV1) is a member of the superfamily of transient receptor potential ion

*Address correspondence to this author at the Department of Anesthesiology and Perioperative Medicine, Pain Research Center, Brigham and Women's Hospital, MRB-611 75 Francis Street, Boston, MA 02115; E-mail: ssuzuki@zeus.bwh.harvard.edu

homologous alpha-subunit genes. The nine subtypes now known in mammals (Na_v1.1 through 1.9) are differentially expressed in various tissues, which suggests their functional correlation. For example, multiple subtypes of sodium channels in the dorsal root ganglion (DRG) are believed to be involved in multiple events along the pain pathway such as transmission, signal amplification, and action potential electrogenesis. Nociceptors express several types of sodium channels including both TTX-sensitive (Na_v 1.1, 1.6, 1.7 and 1.3) and TTX-resistant (Na_v 1.8 and 1.9) subtypes. Some of the sodium channels such as Na_v1.8, Na_v1.9, and Na_v 1.7 are expressed exclusively on peripheral [33-35] but not vagal [36] nociceptors.

Currently the “hottest” target for nociceptive-specific blockade is the Na_v1.7 channel, since this subtype determines the ability of a nerve to transmit pain sensation [37].

The importance of Na_v 1.7 has become increasingly evident through genetic correlation of this channel with congenital abnormality of pain perception [38]. Loss-of-function mutations of Na_v1.7 are reported in patients with channelopathy-associated insensitivity, in which patients have isolated lack of sensory function for pain and smell [37]. On the other hand, several gain-of-function mutations of genes related to the regulation or function of Na_v1.7, resulting in over-activity of this channel, are found in patients with two painful congenital disorders, erythralgia (also termed erythremelalgia) and paroxysmal extreme pain disorder, congenital conditions whereby patients are afflicted by episodic severe pain attacks accompanied by cutaneous flushing [39-41]. Na_v1.7 also appears to be involved in the development of inflammatory pain, as demonstrated in an animal study that showed inflammation-induced upregulation of Na_v1.7 in the DRG [42]. Furthermore, a recent preclinical study has reported that ProTX-II, a Na_v1.7-selective antagonist from spider venom, prevented the propagation of action potentials in small-diameter nociceptive fibers, while larger fibers remained intact [43]. The further identification of such a selective Na_v1.7 blocker is an area of great interest.

Na_v1.8 is expressed predominantly in small nociceptive neurons [34] and has been demonstrated to be the main source of sodium influx during action potential electrogenesis [44, 45]. Knock-out (KO) studies demonstrated that this channel also underlies the ability of nociceptive neurons to fire repetitively [46]. Accumulating evidence has shown the intimate relationship of Na_v1.8 to generation of inflammatory and neuropathic pain [46-51]. The injection of complete Freund's adjuvant or carageenan increased expression of Na_v1.8 in the rat DRG. In mice, knocking down the Na_v1.8 gene by antisense oligonucleotides attenuated the development of inflammatory hyperalgesia [52,53]. Currently A-803467, a Na_v1.8-selective blocker, has been shown to attenuate mechanical allodynia in a dose-dependent fashion in animal pain models including sciatic nerve injury, spinal nerve ligation, and chemically induced thermal allodynia and secondary allodynia [51, 54]. Ambroxol, a relatively selective blocker of Na_v1.8, has also been shown to produce effective analgesia in inflammatory and neuropathic pain models in animals[55]. Another subtype,

Na_v1.9, is also found only in small DRG neurons [51, 56-58]. Na_v1.9 is thought to be responsible for a slow persistent sodium current with low threshold and activated over a wide range of voltage. This current is postulated to influence the subthreshold excitable properties of the membrane, which may explain the mechanism of sensitization by causing the membrane resting potential to fluctuate [46, 49, 57, 59]. In addition, Na_v1.9 KO mice failed to display inflammation-induced excitability or up-regulation of Na_v channels[60]. Subsequent introduction of cloned Na_v1.9 reinstated this effect[60].

The differential effect on nociceptive-specific sodium channels may also underlie the analgesic effects of some anticonvulsants and antidepressants. For example, Lacosamide is an anticonvulsant that also has Na_v1.8-blocking properties and has been shown to be effective in treating neuropathic pain in preclinical studies[61].

The restricted expression of sodium channels Na_v1.7, Na_v1.8, and Na_v1.9 on peripheral nociceptors and the direct link of Nav1.7 to pain states in humans make them ideal targets for development of more effective drugs with fewer undesirable side effects. However, since specific blockers of sodium channels demonstrate low bioavailability, none of the existing compounds have proven suitable for clinical use. Recently demonstrated expression of TTX-resistant sodium channels on A-fibers of nodose vagal sensory neurons reduce the selectivity of these specific blockers to nociceptors [36]. Moreover, chronic pain disorders are multifactorial, and the efficacy of drugs is also greatly influenced by the up- and down-regulation of various sodium channel subtypes in the different stages of inflammatory and neuropathic pain [50, 62-66].

Therefore the approaches targeting sodium channel blockers specifically to nociceptive neurons are preferable.

FUTURE STUDIES

Many compounds targeting specific sodium channel subtypes have been identified and are currently awaiting detailed testing *in vivo* in various models. Among them, the above-mentioned A-803467 appears promising in treating neuropathic and inflammatory pain. However, no clinical trials are currently underway using this agent (clinical-trials.gov). Lacosamide is now under phase 3 clinical trials for mainly neuropathic pain such as painful diabetic neuropathy, migraine, and post-herpetic neuralgia. Ralfinamide is also in phase 2 clinical trials for various neuropathic pain conditions.

Besides capsaicin and RTX, further interest in nociceptive-selective blockade may be explored among the members of TRP ion channel family agonists or antagonists. Given the suggested critical role of TRP channels in the pain pathways in both the central and peripheral nervous systems, the surge of interest in the TRP family as a target for the next generation of analgesic agents has led to the discovery of numerous TRP agonists and antagonists. Some of the clinically used local and inhalation anesthetic agents are now known to be TRPV1 and TRPA1 agonists, including lidocaine, tramadol, and isoflurane [67-69]. These agents may generate synergistic differential analgesic effects with other local or general anesthetics through mechanisms similar to

RTX and capsaicin and are potential candidates for future studies to achieve differential nerve block. However, one drawback is that manipulation of TRPV1 activity also affects its thermoregulatory function. It has been demonstrated in both human and animal studies that TRPV1 blockade can lead to hyperthermia in susceptible individuals [70, 71]. These results obviously pose significant challenges to the clinical use of TRPV1 antagonists. Nonetheless, these results are informative for future study of the role of TRPV1 channel activation in thermoregulatory processes. Further research will hopefully identify other, more selective TRPV1 antagonists that they interfere only with the nociceptive transmission while sparing other TRPV1-mediated activities.

Besides identifying drugs for pain-specific sodium channel subtypes and/or TRPV1 agonist/antagonists, and combining TRPV1 channel agonists with permanently charged LAs (Fig. 2), another future approach might be to combine TRPV1 channel agonists with specific positively charged sodium channel subtype antagonists to further maximize pain selectivity. The combination of a TRPV1 agonist and LA is currently awaiting regulatory approval for clinical trials.

In summary, several approaches are currently being pursued in the development of agents for C-fiber-selective peripheral nerve blockade. A considerable amount of effort has been put into identification of compounds specific for sodium channel subtypes and TRP agonists as well as antagonists. An exciting new approach is combining TRPV1 agonists with permanently charged large LA molecules, [31] selectively allowing these otherwise impermeable compounds only into C-fibers.

REFERENCES

- [1] Strichartz GR, Berde CB. Local Anesthetics. In: Miller R.D, Ed. Miller's Anesthesia. 6th ed. New York: Churchill Livingstone; 2004; pp. 573-603.
- [2] Gokin AP, Philip B, Strichartz GR. Preferential block of small myelinated sensory and motor fibers by lidocaine: *in vivo* electrophysiology in the rat sciatic nerve. *Anesthesiology* 2001; 95(6): 1441-54.
- [3] Woolf CJ, Ma Q. Nociceptors--noxious stimulus detectors. *Neuron* 2007; 55(3): 353-64.
- [4] Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. *Nature* 1997; 389(6653): 816-24.
- [5] Lawson JJ, McIlwrath SL, Woodbury CJ, Davis BM, Koerber HR. TRPV1 unlike TRPV2 is restricted to a subset of mechanically insensitive cutaneous nociceptors responding to heat. *J Pain* 2008; 9(4): 298-308.
- [6] Jordt SE, Bautista DM, Chuang HH, *et al.* Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. *Nature* 2004; 427(6971): 260-5.
- [7] Peier AM, Moqrich A, Hergarden AC, *et al.* A TRP channel that senses cold stimuli and menthol. *Cell* 2002; 108(5): 705-15.
- [8] Souslova V, Cesare P, Ding Y, *et al.* Warm-coding deficits and aberrant inflammatory pain in mice lacking P2X3 receptors. *Nature* 2000; 407(6807): 1015-7.
- [9] Macpherson LJ, Xiao B, Kwan KY, *et al.* An ion channel essential for sensing chemical damage. *J Neurosci* 2007; 27(42): 11412-5.
- [10] Burnstock G, Wood JN. Purinergic receptors: their role in nociception and primary afferent neurotransmission. *Curr Opin Neurobiol* 1996; 6(4): 526-32.
- [11] Julius D, Basbaum AI. Molecular mechanisms of nociception. *Nature* 2001; 413(6852): 203-10.
- [12] Butterworth JF, Strichartz GR. Molecular mechanisms of local anesthesia: a review. *Anesthesiology* 1990; 72(4): 711-34.
- [13] Tominaga M, Caterina MJ, Malmberg AB, *et al.* The cloned capsaicin receptor integrates multiple pain-producing stimuli. *Neuron* 1998; 21(3): 531-43.
- [14] Toledo-Aral JJ, Moss BL, He ZJ, *et al.* Identification of PN1, a predominant voltage-dependent sodium channel expressed principally in peripheral neurons. *Proc Natl Acad Sci USA* 1997; 94(4): 1527-32.
- [15] Felts PA, Yokoyama S, Dib-Hajj S, Black JA, Waxman SG. Sodium channel alpha-subunit mRNAs I, II, III, NaG, Na6 and hNE (PN1): different expression patterns in developing rat nervous system. *Brain Res Mol Brain Res* 1997; 45(1): 71-82.
- [16] Djouhri L, Newton R, Levinson SR, Berry CM, Carruthers B, Lawson SN. Sensory and electrophysiological properties of guinea-

Fig. (2). Sciatic nerve block with 0.2 ml of N-methyl amitriptyline at 0.125 %, alone or in combination with 0.05 % capsaicin (simultaneously applied/mixed or 10 min later), n=8 rats per group. Data are presented as mean \pm SE. **A.** Motor Block Score (0-3): Motor function was assayed by a digital platform balance. 0 = no block (or baseline); 1 = minimal block; 2 = moderate block; 3 = complete block (force of 20 g or less). **B.** Superficial Nociceptive Block Score (0-3): Nociception was evaluated by the nocifensive withdrawal reflex and vocalization to pinch of a skin fold. 3 = complete block, no nocifensive reaction or vocalization; 2 = moderate block, vocalization accompanied by slow withdrawal and flexion of the leg; 1 = minimal block, brisk flexion of the leg, with some sideways movement of the body or other escape response and loud vocalization; 0 = baseline with no block and all nocifensive responses listed above.

- pig sensory neurones expressing Nav 1.7 (PN1) Na⁺ channel alpha subunit protein. *J Physiol* 2003; 546(Pt 2): 565-76.
- [17] Sangameswaran L, Fish LM, Koch BD, *et al.* A novel tetrodotoxin-sensitive, voltage-gated sodium channel expressed in rat and human dorsal root ganglia. *J Biol Chem* 1997; 272(23): 14805-9.
- [18] Gibson SJ, McGregor G, Bloom SR, Polak JM, Wall PD. Local application of capsaicin to one sciatic nerve of the adult rat induces a marked depletion in the peptide content of the lumbar dorsal horn. *Neuroscience* 1982; 7(12): 3153-62.
- [19] Knotkova H, Pappagallo M, Szallasi A. Capsaicin (TRPV1 Agonist) Therapy for Pain Relief: Farewell or Revival? *Clin J Pain* 2008; 24(2): 142-54.
- [20] Cortright DN, Krause JE, Broom DC. TRP channels and pain. *Biochim Biophys Acta* 2007; 1772(8): 978-88.
- [21] Cruz F, Dinis P. Resiniferatoxin and botulinum toxin type A for treatment of lower urinary tract symptoms. *Neurourol Urodyn* 2007; 26(6 Suppl): 920-7.
- [22] Cruz CD, Charrua A, Vieira E, Valente J, Avelino A, Cruz F. Intrathecal delivery of resiniferatoxin (RTX) reduces detrusor overactivity and spinal expression of TRPV1 in spinal cord injured animals. *Exp Neurol* 2008; 214(2): 301-8.
- [23] MacDonald R, Monga M, Fink HA, Wilt TJ. Neurotoxin treatments for urinary incontinence in subjects with spinal cord injury or multiple sclerosis: a systematic review of effectiveness and adverse effects. *J Spinal Cord Med* 2008; 31(2): 157-65.
- [24] Saitoh C, Chancellor MB, de Groat WC, Yoshimura N. Effects of intravesical instillation of resiniferatoxin on bladder function and nociceptive behavior in freely moving, conscious rats. *J Urol* 2008; 179(1): 359-64.
- [25] Mourtzoukou EG, Iavazzo C, Falagas ME. Resiniferatoxin in the treatment of interstitial cystitis: a systematic review. *Int Urogynecol J Pelvic Floor Dysfunct* 2008; 19(11): 1571-6.
- [26] Kissin I, Bright CA, Bradley EL, Jr. Selective and long-lasting neural blockade with resiniferatoxin prevents inflammatory pain hypersensitivity. *Anesth Analg* 2002; 94(5): 1253-8.
- [27] Kissin I, Davison N, Bradley EL, Jr. Perineural resiniferatoxin prevents hyperalgesia in a rat model of postoperative pain. *Anesth Analg* 2005; 100(3): 774-80.
- [28] Kissin I, Freitas CF, Bradley EL, Jr. Memory of pain: the effect of perineural resiniferatoxin. *Anesth Analg* 2006; 103(3): 721-8.
- [29] Kissin I, Freitas CF, Bradley EL, Jr. Perineural resiniferatoxin prevents the development of hyperalgesia produced by loose ligation of the sciatic nerve in rats. *Anesth Analg* 2007; 104(5): 1210-6.
- [30] Binshtok AM, Bean BP, Woolf CJ. Inhibition of nociceptors by TRPV1-mediated entry of impermeant sodium channel blockers. *Nature* 2007; 449(7162): 607-10.
- [31] Gerner P, Binshtok AM, Wang CF, *et al.* Capsaicin combined with local anesthetics preferentially prolongs sensory/nociceptive block in rat sciatic nerve. *Anesthesiology* 2008; 109(5): 872-8.
- [32] Kissin I. Vanilloid-induced conduction analgesia: selective, dose-dependent, long-lasting, with a low level of potential neurotoxicity. *Anesth Analg* 2008; 107(1): 271-81.
- [33] Djouhri L, Fang X, Okuse K, Wood JN, Berry CM, Lawson SN. The TTX-resistant sodium channel Nav1.8 (SNS/PN3): expression and correlation with membrane properties in rat nociceptive primary afferent neurons. *J Physiol* 2003; 550(Pt 3): 739-52.
- [34] Akopian AN, Sivilotti L, Wood JN. A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. *Nature* 1996; 379(6562): 257-62.
- [35] Black JA, Dib-Hajj S, McNabola K, *et al.* Spinal sensory neurons express multiple sodium channel alpha-subunit mRNAs. *Brain Res Mol Brain Res* 1996; 43(1-2): 117-31.
- [36] Kwong K, Carr MJ, Gibbard A, *et al.* Voltage-gated sodium channels in nociceptive versus non-nociceptive nodose vagal sensory neurons innervating guinea pig lungs. *J Physiol* 2008; 586(5): 1321-36.
- [37] Cox JJ, Reimann F, Nicholas AK, *et al.* An SCN9A channelopathy causes congenital inability to experience pain. *Nature* 2006; (7121): 894-8.
- [38] Yang Y, Wang Y, Li S, *et al.* Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythralgia. *J Med Genet* 2004; 41(3): 171-4.
- [39] Dib-Hajj SD, Estacion M, Jarecki BW, *et al.* Paroxysmal extreme pain disorder M1627K mutation in human Nav1.7 renders DRG neurons hyperexcitable. *Mol Pain* 2008; 4:37.
- [40] Jarecki BW, Sheets PL, Jackson JO, Cummins TR. Paroxysmal extreme pain disorder mutations within the D3/S4-S5 linker of Nav1.7 cause moderate destabilization of fast inactivation. *J Physiol* 2008; 586(Pt 17): 4137-53.
- [41] Estacion M, Dib-Hajj SD, Benke PJ, *et al.* Nav1.7 gain-of-function mutations as a continuum: A1632E displays physiological changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations and produces symptoms of both disorders. *J Neurosci* 2008; 28(43): 11079-88.
- [42] Black JA, Liu S, Tanaka M, Cummins TR, Waxman SG. Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. *Pain* 2004; 108(3): 237-47.
- [43] Schmalhofer WA, Calhoun J, Burrows R, *et al.* ProTx-II, a selective inhibitor of Nav1.7 sodium channels, blocks action potential propagation in nociceptors. *Mol Pharmacol* 2008; 74(5): 1476-84.
- [44] Renganathan M, Cummins TR, Waxman SG. Contribution of Na(v)1.8 sodium channels to action potential electrogenesis in DRG neurons. *J Neurophysiol* 2001; 86(2): 629-40.
- [45] Blair NT, Bean BP. Roles of tetrodotoxin (TTX)-sensitive Na⁺ current, TTX-resistant Na⁺ current, and Ca²⁺ current in the action potentials of nociceptive sensory neurons. *J Neurosci* 2002; 22(23): 10277-90.
- [46] Akopian AN, Souslova V, England S, *et al.* The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. *Nat Neurosci* 1999; 2(6): 541-8.
- [47] Coward K, Plumpton C, Facer P, *et al.* Immunolocalization of SNS/PN3 and NaN/SNS2 sodium channels in human pain states. *Pain* 2000; 85(1-2): 41-50.
- [48] Laird JM, Souslova V, Wood JN, Cervero F. Deficits in visceral pain and referred hyperalgesia in Nav1.8 (SNS/PN3)-null mice. *J Neurosci* 2002; 22(19): 8352-6.
- [49] Amaya F, Shimosato G, Kawasaki Y, *et al.* Induction of CB(1) cannabinoid receptor by inflammation in primary afferent neurons facilitates antihyperalgesic effect of peripheral CB(1) agonist. *Pain* 2006; 124(1-2): 175-83.
- [50] Amir R, Argoff CE, Bennett GJ, *et al.* The role of sodium channels in chronic inflammatory and neuropathic pain. *J Pain* 2006; 7(5 Suppl 3): S1-29.
- [51] Jarvis MF, Honore P, Shieh CC, *et al.* A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. *Proc Natl Acad Sci USA* 2007; 104(20): 8520-5.
- [52] Yoshimura N, Seki S, Novakovic SD, *et al.* The involvement of the tetrodotoxin-resistant sodium channel Na(v)1.8 (PN3/SNS) in a rat model of visceral pain. *J Neurosci* 2001; 21(21): 8690-6.
- [53] Porreca F, Lai J, Bian D, *et al.* A comparison of the potential role of the tetrodotoxin-insensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain. *Proc Natl Acad Sci USA* 1999; 96(14): 7640-4.
- [54] McGaraughty S, Chu KL, Scanio MJ, Kort ME, Faltynek CR, Jarvis MF. A selective Nav1.8 sodium channel blocker, A-803467 [5-(4-chlorophenyl)-N-(3,5-dimethoxyphenyl)furan-2-carboxamide], attenuates spinal neuronal activity in neuropathic rats. *J Pharmacol Exp Ther* 2008; 324(3): 1204-11.
- [55] Gaida W, Klinder K, Arndt K, Weiser T. Ambroxol, a Nav1.8-preferring Na⁽⁺⁾ channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain. *Neuropharmacology* 2005; 49(8): 1220-7.
- [56] Dib-Hajj SD, Black JA, Cummins TR, Kenney AM, Kocsis JD, Waxman SG. Rescue of alpha-SNS sodium channel expression in

- small dorsal root ganglion neurons after axotomy by nerve growth factor *in vivo*. *J Neurophysiol* 1998; 79(5): 2668-76.
- [57] Wood JN, Boorman JP, Okuse K, Baker MD. Voltage-gated sodium channels and pain pathways. *J Neurobiol* 2004; 61(1): 55-71.
- [58] Fang X, Djouhri L, McMullan S, *et al*. Intense isolectin-B4 binding in rat dorsal root ganglion neurons distinguishes C-fiber nociceptors with broad action potentials and high Nav1.9 expression. *J Neurosci* 2006; 26(27): 7281-92.
- [59] Waxman SG, Estacion M. Nav1.9, G-proteins, and nociceptors. *J Physiol* 2008; 586(4): 917-8.
- [60] Ostman JA, Nassar MA, Wood JN, Baker MD. GTP up-regulated persistent Na⁺ current and enhanced nociceptor excitability require Nav1.9. *J Physiol* 2008; 586(4): 1077-87.
- [61] Sheets PL, Heers C, Stoehr T, Cummins TR. Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine. *J Pharmacol Exp Ther* 2008; 326(1): 89-99.
- [62] Lai J, Porreca F, Hunter JC, Gold MS. Voltage-gated sodium channels and hyperalgesia. *Annu Rev Pharmacol Toxicol* 2004; 44: 371-97.
- [63] Carter AJ, Grauert M, Pschorn U, *et al*. Potent blockade of sodium channels and protection of brain tissue from ischemia by BIII 890 CL. *Proc Natl Acad Sci USA* 2000; 97(9): 4944-9.
- [64] Waxman SG, Cummins TR, Dib-Hajj S, Fjell J, Black JA. Sodium channels, excitability of primary sensory neurons, and the molecular basis of pain. *Muscle Nerve* 1999; 22(9): 1177-87.
- [65] Yu FH, Catterall WA. Overview of the voltage-gated sodium channel family. *Genome Biol* 2003; 4(3): 207.
- [66] Goldin AL. Resurgence of sodium channel research. *Annu Rev Physiol* 2001; 63: 871-94.
- [67] Marincsak R, Toth BI, Czifra G, Szabo T, Kovacs L, Biro T. The analgesic drug, tramadol, acts as an agonist of the transient receptor potential vanilloid-1. *Anesth Analg* 2008; 106(6): 1890-6.
- [68] Leffler A, Fischer MJ, Rehner D, *et al*. The vanilloid receptor TRPV1 is activated and sensitized by local anesthetics in rodent sensory neurons. *J Clin Invest* 2008; 118(2): 763-76.
- [69] Matta JA, Cornett PM, Miyares RL, Abe K, Sahibzada N, Ahern GP. General anesthetics activate a nociceptive ion channel to enhance pain and inflammation. *Proc Natl Acad Sci USA* 2008; 105(25): 8784-9.
- [70] Gavva NR, Treanor JJ, Garami A, *et al*. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. *Pain* 2008; 136(1-2): 202-10.
- [71] Steiner AA, Turek VF, Almeida MC, *et al*. Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors. *J Neurosci* 2007; 27(28): 7459-68.

Received: December 15, 2008

Revised: January 16, 2009

Accepted: January 26, 2009

© Suzuki *et al.*; Licensee Bentham Open.

This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.